Cloning antibodies from recovered COVID-19 patients is showing promise as a potential treatment for the virus that has affected more than 2.8 million people worldwide and killed at least 196,000.

Dr. William A. Haseltine, Chair and President of ACCESS Health International and former Harvard Medical School professor, told uPolitics that an antibody drug could be approved in the U.S. within four months.

Leave a comment